TetraLogic to Present at the 13th Annual Needham Healthcare Conference
March 31 2014 - 7:30AM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that J. Kevin Buchi, President and Chief Executive
Officer, will present at the 13th Annual Needham Healthcare
Conference on Tuesday, April 8, 2014 at 10:40 a.m. Eastern Time in
New York, NY. Mr. Buchi will provide an overview of the Company and
its corporate activities.
The presentation will be webcast live and may be accessed by
visiting TetraLogic's website at
http://ir.tetralogicpharma.com. A replay of the webcast will
be available for 10 business days.
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics
that mimic the Second Mitochondrial Activator of Caspases, or
SMAC-mimetics, and are designed to cause or enable abnormal cells
that are resistant to the body's immune system to self-destruct.
Birinapant, our clinical-stage product candidate, is
currently being tested in Phase 1 and Phase 2 clinical trials for
hematological malignancies and solid tumors.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024